LOG IN/REGISTER >
FORWARD TO A COLLEAGUE >
INDICATION/SAFETY INFORMATION >

Genentech is committed to helping you improve your facility's stroke treatment and patient care. Here are a variety of materials designed to:

  • Raise stroke awareness
  • Educate on the signs, symptoms, and urgent nature of stroke
  • Encourage healthcare provider preparedness and rapid intervention in stroke systems of care
  • Support your stroke center's commitment to striving for excellence

Image library

Image libraryCreate your own stroke advocacy and education materials using downloadable Activase F.A.S.T., Brain, and Golden Hour artwork.

F.A.S.T. materials

F.A.S.T. materialsThe F.A.S.T. system is designed to be a quick prehospital stroke screening tool that assesses facial expression, arm movement, and speech function. This is available as a wallet card, poster, and downloadable fact sheet.

DOWNLOAD OR ORDER

EMS Fact Sheet

EMS fact sheetProvides emergency services personnel with at-a-glance guidelines designed to help assess and manage suspected stroke patients both on the scene and in transit. This fact sheet includes 2 prehospital stroke assessment scales as well as information on Activase (Alteplase).

DOWNLOAD OR ORDER

Quality Assessment Tracker

Quality assessment trackerHelps you support your institution's commitment to quality stroke care by utilizing the downloadable tracking log for important quality measures for stroke response. You'll also find ideas you may wish to incorporate from the best practices provided by 3 Stroke Centers of Excellence.

DOWNLOAD

In-service Knowledge Check

In-service knowledge checkHelps to keep you and your stroke team up to speed on stroke assessment, diagnosis, and treatment with Activase (t-PA) and supports your yearly stroke educational requirement.

DOWNLOAD OR ORDER

Golden Hour Poster

Golden hour posterProvides helpful tips from successful stroke centers on how to improve stroke reaction, assessment, diagnosis, and treatment time in order to stay within the NIH-recommended "golden hour."

DOWNLOAD OR ORDER

Activase (t-PA) Dosing and Administration Poster

Activase (t-PA) dosing and administration posterOutlines step-by-step instructions on the dosing and administration of Activase (t-PA) for eligible acute ischemic stroke patients.

DOWNLOAD OR ORDER

Get With the Guidelines (GWTG)–Stroke

Offered by the American Heart Association, GWTG–Stroke is a quality improvement program for hospitals treating patients with stroke. The goal of GWTG–Stroke is simply to help hospitals save more lives by optimizing care to align with evidence-based guidelines. Download or order the study by Lee H. Schwamm, MD, to read more about the correlation between guideline adherence and improved
stroke care.

ORDER

To download or order additional resources on stroke education and Activase (t-PA) treatment for your institution, visit the Resource Center.

Indication
Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).

Safety Information
Activase therapy in patients with AIS is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation, recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000) (see CONTRAINDICATIONS for full list).

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

The risks of Activase therapy may be increased and should be weighed against the anticipated benefits in certain conditions. [See WARNINGS in full prescribing information].

  • Patients with severe neurological deficit (eg, NIHSS >22) at presentation. There is an increased risk of intracranial hemorrhage in these patients.
  • Patients with major early infarct signs on a computerized cranial tomography (CT) scan (eg, substantial edema, mass effect, or midline shift).

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

Please click here for full prescribing information.